RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis
Authors:
- 1 December 2015
- journal article
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 99 (3) , 498-505
Abstract
No abstract availableKeywords
Funding Information
- Teva Neuroscience
- Veterans Administration Merit (BX001458)
- Foundation of the Consortium of Multiple Sclerosis Centers' MS Workforce of the Future
- University of Maryland School of Medicine Office of Student Research
- Leslie B. Barnett Memorial Student Fellowship
- University of Maryland School of Medicine Office of Student Research
This publication has 21 references indexed in Scilit:
- Biomarkers in multiple sclerosisClinical Immunology, 2015
- Biomarkers of disease activity in multiple sclerosisJournal of the Neurological Sciences, 2011
- A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosisJournal of Neurology, 2010
- Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cellsExperimental and Molecular Pathology, 2009
- Death Ligands and Autoimmune DemyelinationThe Neuroscientist, 2006
- RGC-32 Increases p34CDC2 Kinase Activity and Entry of Aortic Smooth Muscle Cells into S-phaseJournal of Biological Chemistry, 2002
- Molecular Cloning and Characterization of RGC-32, a Novel Gene Induced by Complement Activation in OligodendrocytesJournal of Biological Chemistry, 1998
- Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disabilityNeurology, 1998
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- Rating neurologic impairment in multiple sclerosisNeurology, 1983